Adverse effects of GLP – 1 Receptor Agonists

Adverse effects of GLP – 1 Receptor Agonists

Introduction and purpose Glucagon-like peptide-1 receptor agonists (GLP – 1 RAs) are indicated in type 2 diabetes (T2D) and obesity because of their high efficacy in controlling blood glucose levels and inducing weight loss. Patients may develop gastrointestinal adverse effects (GI AEs) such as nau...

Full description

Saved in:

Bibliographic Details
Main Authors:	Anna Kasprzak, Monika Kułaga, Monika Grzybek, Diana Mazur-Lesińska, Barbara Szostak, Sylwia Wielgosz-Biała, Krzysztof Tyszkiewicz, Borys Łozowski, Małgorzata Kasprzak, Barbara Wilczyńska
Format:	Article
Language:	English
Published:	Kazimierz Wielki University 2025-02-01
Series:	Journal of Education, Health and Sport
Subjects:	type 2 diabetes obesity, glucagon – like peptide – 1 receptor agonists hypoglycemia gastrointestinal adverse effects nonarteritic anterior ischaemic optic neuropathy
Online Access:	https://apcz.umk.pl/JEHS/article/view/57774
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

GLP-1 receptor agonists in diabetes and weight loss: the double-edged sword of innovation and risks
by: Ioannis Ilias, et al.
Published: (2025-01-01)

Semaglutide, type 2 diabetes, and the risk of nonarteritic anterior ischemic optic neuropathy
by: Fernando K. Malerbi, et al.
Published: (2025-01-01)

One step closer to solving the mystery of the anti‐inflammatory effects of glucagon‐like peptide‐1 receptor agonists
by: Hirotaka Watada
Published: (2025-02-01)

Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes
by: Jakob Grauslund, et al.
Published: (2024-12-01)

Incretin hormone agonists as promising antiobesity drugs - review of literature
by: Aleksandra Grzegorczyk, et al.
Published: (2025-01-01)

Effect of glucagon-like peptide-1 receptor agonists on vascular risk factors among adults with type 2 diabetes and established atherosclerotic cardiovascular disease
by: Aaron King, et al.
Published: (2025-03-01)

The impact of glucagon-like peptide-1 (GLP-1) agonists in the treatment of eating disorders: a systematic review and meta-analysis
by: Hanieh Radkhah, et al.
Published: (2025-02-01)

The protective role of GLP-1 in neuro-ophthalmology
by: Sohum Sheth, et al.
Published: (2023-08-01)

Enhanced renoprotective effects of combined glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: Real‐world evidence
by: Jian‐Yu Jhu, et al.
Published: (2025-02-01)

Efficacy and safety of glucagon-like peptide-1 receptor agonists in the elderly versus non-elderly patients with type 2 diabetes mellitus: insights from a systematic review
by: Yao Wang, et al.
Published: (2024-06-01)

Glucagon like peptide-1 (GLP-1) agonists and cardiometabolic protection: historical development and future challenges
by: Francisco Westermeier, et al.
Published: (2025-01-01)

Managing cardiovascular events, hyperglycemia, and obesity in type 2 diabetes through microRNA regulation linked to glucagon-like peptide-1 receptor agonists
by: Xiaolei Miao, et al.
Published: (2025-01-01)

Use of Glucagon-Like Peptide-1 Receptor Agonists Does Not Increase the Risk of Cancer in Patients with Type 2 Diabetes Mellitus
by: Mijin Kim, et al.
Published: (2025-01-01)

Foundational contributions of Svetlana Mojsov to the GLP-1 field
by: George Barany, et al.
Published: (2024-10-01)

Impact of Hospitalization on Continuation of SGLT2 Inhibitors and GLP-1 Receptor Agonists for Comorbidities in Patients with Type 2 Diabetes
by: Bethany Murphy, et al.
Published: (2025-01-01)

GLP‐1 Receptor Agonists Alleviate Diabetic Kidney Injury via β‐Klotho‐Mediated Ferroptosis Inhibition
by: Shasha Tian, et al.
Published: (2025-01-01)

The Beneficial Effects of GLP-1 Receptor Agonists Other than Their Anti-Diabetic and Anti-Obesity Properties
by: Chenqi Lu, et al.
Published: (2024-12-01)

Are obese rats influenced by GLP1 and IR through aerobic exercise? A case study
by: Ali Sayyah, et al.
Published: (2016-08-01)

Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical Evidence
by: Srikanth Krishnan, et al.
Published: (2025-01-01)

Characterization of LY3324954 a long-acting glucagon-receptor agonist
by: William Roell, et al.
Published: (2025-01-01)

Real-world clinical evidence of oral semaglutide on metabolic abnormalities in subjects with type 2 diabetes: a multicenter retrospective observational study (the Sapporo-Oral SEMA study)
by: Sho Furusawa, et al.
Published: (2024-06-01)

Review: Agonistics. Thinking the World Politically de Chantal Mouffe
by: José Fernández Vega
Published: (2014-01-01)

Chemotherapy in synergy with innate immune agonists enhances T cell priming for checkpoint inhibitor treatment in pancreatic cancer
by: Nan Niu, et al.
Published: (2025-01-01)

Potential benefits of GLP-1 analogues and metformin in patients with osteoarthritis
by: Anna Skowronek, et al.
Published: (2025-01-01)

Response to ‘Commentary on the published position statement regarding the pathogenesis of fetal basal ganglia- thalamic hypoxic-ischaemic injury’ (Anthony et al.)
by: I Bhorat, et al.
Published: (2023-12-01)

The agony and the efficacy: central mechanisms of GLP-1 induced adverse events and their mitigation by GIP
by: Jonathan D. Douros, et al.
Published: (2025-02-01)

A Case of Persistent Hypoglycemia: Emphasizing the Role of Kidneys
by: Praveen Govindaraju, et al.
Published: (2024-04-01)

Case report: Kabuki syndrome and persistent hypoglycemia in neonates
by: Osama Y Safdar, et al.
Published: (2024-12-01)

Acute response of intermittent and continuous aerobic exercises on blood glucose of adolescents
by: Valderi Lima, et al.
Published: (2017-07-01)

Different post-pancreatectomy glucagon responses to a meal test between surgical approaches
by: Tsuguka Matsuda, et al.
Published: (2023-11-01)

Obstructive sleep apnea, the NLRP3 inflammasome and the potential effects of incretin therapies
by: Michelle Wei, et al.
Published: (2025-01-01)

From Clinical Trial Evidence to Clinical Guidelines: Perspectives on REWIND from Clinicians in the Gulf and Levant Region
by: Talal Ashour, et al.
Published: (2023-11-01)

Impact of Thrombopoietin Receptor Agonists on Pathophysiology of Pediatric Immune Thrombocytopenia
by: Paschalis Evangelidis, et al.
Published: (2025-01-01)

A Purely Biomanufactured System for Delivering Nanoparticles and STING Agonists
by: Yu‐an Li, et al.
Published: (2025-01-01)

The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction (HFpEF)
by: Darshan Hullon, et al.
Published: (2025-02-01)

Benzodiazepine agonist treatment for patients with benzodiazepine dependence undergoing opioid agonist treatment: a study protocol for the randomized controlled trial BMX-BAR
by: Fatemeh Chalabianloo, et al.
Published: (2025-01-01)

Is Weight Loss the Main Driver for A1C Improvement by Glucagon‐Like Peptide 1 (GLP‐1) Receptor Agonists? A 2.5‐Year Analysis in Real‐World Clinical Practice
by: Marwa Al‐Badri, et al.
Published: (2025-01-01)

Persistent Hyperinsulinemic Hypoglycemia in Iraqi Pediatric Population: A Single Tertiary Center Experience
by: Munib Ahmed Al-Zubaidi, et al.
Published: (2024-12-01)

Hypoglycemia and hospital mortality in critically ill patients
by: Hsuan-Fan Yeh, et al.
Published: (2025-01-01)

Drug resistant epilepsy as the consequence of inadequate control of type 1 diabetes
by: Ewa M. Sokolewicz, et al.
Published: (2024-04-01)